Global Medical Response



Q2 2026 Earnings Presentation

August 12, 2026

Disclaimers

Forward-Looking Statements: This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect our current views with respect to, among other things, our operations and financial performance. Forward-looking statements include all statements that are not historical facts, including statements related to our 2026 Outlook and financial guidance, our capital allocation framework and priorities, our ability to capture market share and growth, our ability to enable better margins, our ability to capture market share and additional geographies, our ability to unlock new vectors for growth and our multi-pronged strategy (including our ability to cross-sell, pursue disciplined acquisitions, drive higher margins and enhance profitability). These forward-looking statements may relate to matters which include, but are not limited to, industries, business strategy, goals and expectations concerning our market position, future operations, margins, profitability, capital expenditures, liquidity and capital resources and other financial and operating information. In some cases, you can identify these forward-looking statements by the use of words such as "anticipate," "assume," "believe," "can," "continue," "could," "estimate," "expect," "foreseeable," "future," "intend," "may," "plan," "potential," "predict," "project," "seek," "should," "will," "would," the negative version of these words, or similar terms and phrases.

The forward-looking statements are based on management's current expectations and are not guarantees of future performance. The forward-looking statements are subject to various risks, uncertainties, assumptions or changes in circumstances that are difficult to predict or quantify. Our expectations, beliefs and projections are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that management's expectations, beliefs, and projections will result or be achieved. Actual results may differ materially from these expectations due to changes in global, regional or local economic, business, competitive, market, regulatory and other factors, many of which are beyond our control. We believe that these factors include but are not limited to the following: if we receive fewer emergency transport requests or fewer non-emergency ambulance transport requests, our revenue could be adversely effected; shifts in payor mix could decrease our revenue; changes in the rates paid by, or the coverage or reimbursement methodology used by, commercial insurers, and delays in collection or non-collection of our accounts receivable could adversely affect us; reduction in governmental rates for our services, limitations in funding for our services, or reduction in the number of individuals eligible for Medicare and Medicaid programs could adversely impact our business; our business could be materially adversely affected if we are not able to maintain or reduce costs to provide our services; we have a history of losses and can provide no assurance of our future operating results; federal and state "surprise medical billing" legislation and regulations could adversely affect us; deterioration in the collectability of patient responsibility accounts or charges for uninsured patients could reduce our revenue; adverse weather conditions and physical impacts of climate change affect our helicopter emergency air ambulance operations, which could adversely impact our results of operations; the inability to maintain our corporate reputation and relationships with existing patient referral sources or establish new referral sources could materially adversely affect us; loss of existing contracts, including ground ambulance contracts and our EMS partnership with the Federal Emergency Management Agency, could adversely affect our revenue; our inability to attract and retain qualified and skilled personnel could adversely affect us; our business requires substantial capital expenditures and working capital financing, which we may be unable to obtain on satisfactory terms or at all; our dependency on a limited number of third-party vendors for certain equipment and services could impair our ability to obtain the equipment and services we need to operate our business; inflationary pressure, particularly increases in fuel costs, could negatively impact our operations; our emphasis on servicing rural communities exposes us to risks; accidents or other incidents involving patient transport operations could materially and adversely affect our reputation, business, financial condition, results of operations and cash flows; any failure by us to manage or integrate acquisitions, divestitures, and other significant transactions successfully may have a material adverse effect on us; if we fail to manage organizational change effectively, we may be unable to execute our business plan, maintain our high levels of service or adequately address competitive challenges; our business may be materially and adversely affected if we are unable to ensure that our services interoperate with operating systems, devices and software and properly maintain the uninterrupted operation and data integrity of our information technology and other business systems; impairment of our goodwill or other intangible assets may adversely impact us; cybersecurity incidents could disrupt business operations, result in the unauthorized access to or disclosure or use of critical and other sensitive or regulated data or confidential information and adversely impact us; our use or our third-party service providers' or business partners' use of Machine Learning Technologies and the evolving regulatory framework in this area could materially or adversely affect us; we are subject to risks related to payment processing; hospital capacity and the ability of hospitals to treat the patients we transport can impact our business; our business may be harmed by labor relation matters; we may be adversely affected if we are unable to retain any member of our senior management; adverse changes in general economic conditions and reductions in consumer spending could adversely impact the patients and the hospitals that use our services; competition from other air or ground ambulance providers may adversely affect our business; we may be subject to substantial malpractice or other similar claims and insurance coverage for some of our losses may be inadequate and may be subject to the credit risk of commercial insurance companies; the reserves established for our losses covered under insurance programs are subject to inherent uncertainties; risks relating to payments to tax receivable agreement parties for certain tax benefits; risks relating to our compliance with our legal and regulatory framework; continued regulatory and public scrutiny of private equity's role in EMS and healthcare may limit our ability to acquire operations, expand in certain states, or otherwise materially and adversely affect our reputation, business, operations and financial condition; our inability or failure to obtain, maintain, protect or enforce our intellectual property rights could adversely affect our business; our substantial indebtedness could adversely affect our financial condition; we are a "controlled company" within the meaning of the rules of the New York Stock Exchange and the rules of the Securities and Exchange Commission ("SEC") and, as a result, qualify for, and rely on, exemptions from certain corporate governance requirements; Kohlberg Kravis Roberts & Co. Inc., and funds affiliated with it, controls us and its interests may conflict with yours in the future; and regulations limit foreign ownership of us, which could reduce the price of our Class A common stock and cause owners of our Class A common stock who are not U.S. persons to lose their voting rights. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included herein and in our filings with the SEC, including the information under the captions "Risk Factors" in GMR's final prospectus (the "IPO Prospectus") in connection with our initial public offering (the "IPO") filed with the SEC and dated May 12, 2026, as well as GMR's subsequent other filings with the SEC from time to time. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, our actual results may vary in material respects from those projected in these forward-looking statements. Any forward-looking statements made by us herein speak only as of the date of this presentation and are expressly qualified in their entirety by the cautionary statements included herein. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, investments, or other strategic transactions we may make. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. For additional information on these and other factors that could cause GMR's actual results to differ materially from expected results, please see our filings with the SEC, which are accessible on the SEC's website at www.sec.gov and on the "Investor Relations" tab of our website.

Non-GAAP Financial Information: This presentation contains "non-GAAP financial measures," which are financial measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with GAAP. Specifically, we make use of the non-GAAP financial measures "EBITDA," "Adjusted EBITDA," "Adjusted EBITDA Margin," "Net Debt," "Net Leverage" and "Free Cash Flow" (the "Non-GAAP Measures"). We provide non-GAAP financial information to enhance the understanding of our GAAP financial information, and it should be considered by the reader in addition to, but not instead of, the financial statements prepared in accordance with GAAP. Each non-GAAP financial measure is presented along with the corresponding GAAP measure so as not to imply that more emphasis should be placed on the non-GAAP measure. We believe that providing these non-GAAP measures in addition to the GAAP measures allows management, investors and other users of our financial information to more fully and accurately assess performance. The non-GAAP financial information presented may be determined or calculated differently by other companies and may not be directly comparable to that of other companies. We define EBITDA as net income (loss) before interest expense, net, income tax provision (benefit), and depreciation and amortization. We define Adjusted EBITDA as EBITDA, as further adjusted to exclude management fees, non-cash stock-based compensation, professional fees and other expenses for non-recurring matters, debt financing fees paid to (received from) third parties and certain other items that we do not consider indicative of our ongoing operating performance. We define Adjusted EBITDA Margin as Adjusted EBITDA divided by revenue. We define Net Debt as total debt less cash and cash equivalents. We define Net Leverage as net debt divided by Adjusted EBITDA. We define Free Cash Flow as net cash provided by (used in) operating activities less purchases of property and equipment. Management uses the Non-GAAP Measures to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish and award discretionary annual incentive compensation, to report compliance with certain covenants in our debt agreements and to compare our performance against that of peer companies using similar measures. Moreover, we present the Non-GAAP Measures because we believe that investors consider them to be important supplemental measures of our performance and believe these measures are frequently used by securities analysts, investors and other interested parties in the evaluation of companies in our industry. Adjusted EBITDA is an analytical indicator used by management and the healthcare industry to evaluate company performance, allocate resources and measure leverage. Adjusted EBITDA should not be considered in isolation or as an alternative to net income (loss), cash flows from operations, investing or financing activities, or other financial statement data presented in the audited consolidated financial statements as indicators of financial performance. Because Adjusted EBITDA is not a measure determined in accordance with GAAP and is thus susceptible to varying calculations, Adjusted EBITDA as presented may not be comparable to other similarly titled measures of other companies and may not be comparable to similarly titled measures used in debt compliance calculations. Net income (loss) is the financial measure calculated and presented in accordance with GAAP that is most comparable to Adjusted EBITDA, as defined.

Industry and Market Data: Certain data in this presentation was obtained from various external data sources, and the Company has not verified such data with independent sources. Accordingly, the Company makes no representation as to the accuracy or completeness of that data, and such data involves risks and uncertainties and is subject to change based on various factors. The Company undertakes no obligation to update any such data to reflect events or circumstances after the date of this presentation or to reflect new information or the occurrence of unanticipated events, except as required by applicable law. Statements contained herein describing documents and agreements are summaries only and such summaries are qualified in their entirety by reference to such documents and agreements. All trademarks, service marks, and trade names appearing in this presentation are the property of their respective holders.

GMR Solutions Inc. ("GMR") at a Glance

Who We Are

Largest provider of Emergency Medical Services ("EMS") and one of the largest mobile clinical practice groups globally

What We Do

Navigate and provide essential alternate-site, out-of-hospital care for patients when they need us most

How We Do It

Through our highly trained clinicians, support staff and fleet, which rapidly deploy across our fully integrated air and ground model

GMR TODAY[1]

~5.5 Million
Annual Patient Encounters

100+ Years
Delivering Emergent care

~61%
U.S. Population Coverage

~1,400
U.S. Counties Served

$5.9B
LTM Q2'26 Revenue

$35B[3]
Total Addressable Market

$1.2B[2]
LTM Q2'26 Adj. EBITDA

20%[2]
LTM Q2'26 Adj. EBITDA Margin

1. As of June 30, 2026, unless otherwise specified.
2. Adjusted EBITDA is a non-GAAP financial measure. Please see the Appendix to this presentation for the reconciliation of non-GAAP metrics.
3. As of 2023.

Global Medical Response

We Deliver Critical Care at Scale Across the U.S. & Globally

The scale, depth and pace at which we operate is unmatched

An Average Day at GMR

15.0K Daily Patient Encounters	**129** Cardiac Arrest Responses	**177** Emergency Stroke Patients	**137** Critically Injured Trauma Patient Transports
800 Blood Glucose Assessments on Patients With Altered Mental Status	**134** Critical Airway Interventions	**289** Nurse Navigation 911 Call Interventions	**~2.7K** Intravenous Access (IVs)

Note: All figures as LTM June 30, 2026, unless otherwise noted; Average day at GMR calculated by dividing annual stats by 365.

Q2 2026 Financial Highlights

Three months ended June 30, 2026

Revenue ($mm)	Adj-EBITDA[1] ($mm)
$1,490.3	**$284.5**
Revenue Growth	Adj-EBITDA Margin [2] (%)
3.3%	**19.1%**

Business Metrics:

~1.4 million	Total Patient Encounters
+1.4% y/y	NRT[3] Growth
+3.8% y/y	Same Market Revenue Growth

Strong revenue performance driven by Total Patient Encounters, NRT Growth, and Same Market Revenue Growth

1. Adjusted EBITDA is a non-GAAP financial measure. Please see the Appendix to this presentation for the reconciliation of non-GAAP metrics.
2. Adj-EBITDA Margin represents Adj-EBITDA as a percentage of Revenue and is a non-GAAP financial measure. Please see the Appendix to this presentation for the reconciliation of non-GAAP metrics.
3. NRT = Net Transport Revenue per Ambulance Transport.

Q2 2026 Financial Highlights

Three months ended June 30, 2026

Revenue (1)



Adjusted EBITDA (1,2)



Revenue

- 6.9% Air transport volume growth due to strong demand and improved capture rate
- 2.4% Emergent ground transport increase on strong same store demand
- (3.0%) Non-emergent ground transport decrease due to deliberate strategy of shifting to higher acuity transports
- 1.4% Net Revenue per Transport increase due to positive mix-shift to emergent encounters and strong underlying improvements on a like for like basis

Adjusted EBITDA

- 3.3% base crew wage unit cost increase
- Temporary inflation in fuel and fuel-related costs (i.e., travel) due to the Iran Conflict

1. Revenue and Adjusted EBITDA were each impacted by the prior year comparison; the prior year period benefited from favorable revenue estimate developments driven by unusually strong collections on No Surprises Act claims related to prior years of service, resulting in a $74.3 million year-over-year difference in changes in revenue estimates.
2. Adjusted EBITDA is a non-GAAP financial measure. Please see the Appendix to this presentation for the reconciliation of non-GAAP metrics.

Global Medical Response

Q2 2026 Patient Encounter Trends[1]

Three months ended June 30, 2026

(All figures in thousands)

Total Patient Encounters = **Emergent Encounters + Nurse Navigation** + **Non-Emergent Transports** + **Other Non-Transports and Wheelchair Transports**



Encounter Mix		62.5%	64.2%	15.5%	14.9%	22.0%	20.9%

Continued growth in our core competency of emergency services and rationalization of non-emergent and wheelchair services. Non-transports positively impacted (declined) by growth of 911 Nurse Navigation.

1. Please see the 10-Q for definitions of the metrics provided.

Q2 2026 NRT and Payor Mix

Three months ended June 30, 2026

NRT [1,2]



Payor Mix as a Percentage of Net Transport Revenue [2]



NRT increase due to positive mix-shift to emergent encounters and strong underlying improvements on a like for like basis

1. NRT = Net Transport Revenue per Ambulance Transport.
2. NRT and Commercial Payor Mix were each impacted by the prior year comparison; the prior year period benefited from favorable revenue estimate developments driven by unusually strong collections on No Surprises Act claims related to prior years of service, resulting in a $74.3 million year-over-year difference in changes in revenue estimates

Q2 2026 911 Nurse Navigation

Three months ended June 30, 2026

Nurse Navigation Encounters increased from 19.3k in 2Q'25 to 28.9k in 2Q'26 (+49.7% YoY)

- **Markets Nurse Navigation** is deployed increased from 24 in 2Q'25 to 29 in 2Q'26 (+20.8% YoY)
- **The Total Population Covered by Nurse Navigation** increased from 14.8 million lives in 2Q'25 to 19.7 million lives in 2Q'26 (+33.1%YoY)

Nurse Navigation Encounters
(thousands)



Markets Deployed



Population Covered
(millions)



Nurse Navigation saw a 50% year-over-year increase in calls in 2Q'26 and a 33% increase in covered lives

Q2 2026 Liquidity and Debt

Three months ended June 30, 2026

Liquidity
(millions)



Net Leverage (2)



May 2026 Ratings Upgrades

MOODY'S
B2 → B1

S&P Global Ratings
B → B+

Cash and cash equivalents

- $420 million of cash and cash equivalents
- Recently upsized $800 million ABL that is undrawn with ~$696 million of available borrowing capacity after letters of credit
- In May, Moody's and S&P upgraded our credit ratings from B2/B to B1/B+, respectively, triggering a 25-basis point interest rate step down on our term loan facility.

Net Leverage

- 3.5x Net Leverage, with line of sight to 3.0x in 2027

Net Leverage decreased to 3.5x in Q2'26 from 4.3x LTM Post-IPO and Private Placement in Q2'25

1. Represents available capacity under $800mm ABL Revolving Credit facility.
2. Net Leverage is a non-GAAP financial measure. Please see the Appendix to this presentation for the reconciliation of non-GAAP metrics.

2026 Outlook

2026 Outlook Reiterated *(August 13, 2026)*

2026 Net Revenue	2026 Adj. EBITDA[(1)]	Of Revenue for Net Cash CAPEX and Aircraft Financing
$5.890B to $6.180B	$1.135B to $1.195B	5.1% to 5.3%

(1) A reconciliation of the guidance for Adjusted EBITDA to GAAP net income cannot be provided without unreasonable effort because of the inherent difficulty of accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliation that have not yet occurred, are out of our control, or cannot be reasonably predicted. For the same reasons, the Company is unable to assess the probable significance of the unavailable information, which could have a material impact on its future GAAP financial results.

Since 2017, GMR has celebrated the lifesaving care our clinicians provide everyday with the Tomorrow Wall®

Each plaque on the Tomorrow Wall represents one local patient who was successfully resuscitated and discharged from the hospital with no neurological deficits. These walls, which are found at operations throughout the country, represent the thousands of patients who "have a tomorrow" thanks to GMR and our talented caregivers in the field.

Global Medical Response

Appendix

Key Performance Metrics

(in thousands)	Three Months Ended June 30, 2026	Three Months Ended June 30, 2025	Six Months Ended June 30, 2026	Six Months Ended June 30, 2025
Patient encounters				
Emergent transports	845,805	824,170	1,683,248	1,656,043
Non emergent transports	202,529	208,864	407,238	429,448
Total ambulance transports	1,048,334	1,033,034	2,090,486	2,085,491
of which, Ground transports	1,012,182	999,220	2,019,992	2,017,716
of which, Flights	36,152	33,814	70,494	67,775
Wheelchair transports	6,855	16,138	14,683	32,715
Nurse Navigation encounters	28,909	19,308	57,031	38,479
Non-transport	278,480	281,395	552,400	551,672
Total patient encounters	1,362,578	1,349,875	2,714,600	2,708,357
Net transport revenue per ambulance transport	$ 1,370	$ 1,351	$ 1,365	$ 1,305
Other key performance indicators:				
Emergent air transport requests	80,577	76,933	155,790	152,774
Air base count	385	381	385	381
Weather cancellation rate for emergent air transports	15.5 %	18.5 %	16.3 %	18.2 %
Same market revenue growth	3.8 %	12.1 %	5.7 %	13.4 %
Net cash capital expenditures	$ 66,400	$ 40,303	$ 120,411	$ 78,931
Cash used in aircraft financing arrangements	$ 27,486	$ 24,405	$ 52,478	$ 49,500

Global Medical Response

Reconciliations of EBITDA and Adjusted EBITDA to Net Income

(unaudited, in thousands)	TTM	Three Months Ended					
	30-Jun-26	30-Jun-26	31-Mar-26	31-Dec-25	30-Sep-25	30-Jun-25	31-Mar-25
Net revenue	$5,878,220	$1,490,286	$1,457,576	$1,423,490	$1,506,868	$1,442,011	$1,367,407
Net income (loss)	$165,500	($28,278)	$106,336	$12,843	$74,599	$80,761	$38,024
Interest expense, net	360,488	76,848	83,174	93,261	107,205	108,516	113,685
Income tax provision (benefit)	84,575	8,980	36,195	9,514	29,886	41,533	29,367
Depreciation and amortization	334,280	76,956	75,367	108,591	73,366	72,507	75,127
EBITDA	**944,843**	**134,506**	**301,072**	**224,209**	**285,056**	**303,317**	**256,203**
Management fees (1)	10,131	1,744	2,977	2,705	2,705	2,705	2,705
Stock-based compensation (2)	138,748	132,602	(91)	475	5,762	2,987	2,605
Professional fees and other expenses for non-recurring matters (3)	36,887	16,234	6,911	9,250	4,492	2,821	4,554
Debt refinancing fees paid to (received from) third parties (4)	45,718	239	320	6,061	39,098	(10)	383
Impairment of assets held for sale and other investments (5)	—	—	—	—	—	—	14,100
Loss on debt extinguishment (6)	5,745	—	—	—	5,745	—	—
(Gain) loss on divestiture of businesses (7)	—	—	—	—	—	5,259	(1,422)
Realized and unrealized (gain) loss (8)	(6,280)	(353)	(5,674)	260	(513)	5,767	1,235
Equity method investment (income) loss (9)	(668)	(436)	(463)	457	(226)	(272)	(2,302)
Adjusted EBITDA	**$1,175,124**	**$284,536**	**$305,052**	**$243,417**	**$342,119**	**$322,574**	**$278,061**
Net Income Margin	**2.8%**	**-1.9%**	**7.3%**	**0.9%**	**5.0%**	**5.6%**	**2.8%**
Adjusted EBITDA Margin	**20.0%**	**19.1%**	**20.9%**	**17.1%**	**22.7%**	**22.4%**	**20.3%**

1. Represents management/director fees paid to directors and Kohlberg, Kravis, Roberts & Co. L.P. (the Manager) in connection with the ownership and financial management of the Company and procurement diagnostics and operational support provided by the Manager and its affiliates, including under the Monitoring Agreement (as defined in the IPO Prospectus). The Monitoring Agreement was terminated upon completion of the IPO.
2. Represents the stock compensation expense associated with the vesting of stock options and other equity awards, as well as the estimate of achievement of the cash-settled performance stock units.
3. Represents fees and expenses incurred in connection with certain business combinations and divestitures, as well as other fees and expenses incurred in connection with distinct transactions and matters unrelated to our normal and continued business operations.
4. Represents fees associated with our long-term debt refinancing consummated during fiscal year 2025, which primarily consisted of fees incurred for third-party legal, accounting and tax consulting in connection with the debt refinancing.
5. Impairment of assets held for sale and other investments includes impairment charges of $14.1 million related to a strategic cost investment for the six months ended June 30, 2025. There was no impairment on assets held for sale or strategic cost investments for the three and six months ended June 30, 2026.Loss on debt extinguishment represents costs related to the extinguishment of the senior secured PIK notes as part of the long-term debt refinancing consummated during fiscal year 2025.
6. Loss on debt extinguishment represents costs related to the extinguishment of the senior secured PIK notes as part of the long-term debt refinancing consummated during fiscal year 2025.
7. (Gain) loss on divestiture of businesses for the three and six months ended June 30, 2025 was $5.3 million and $3.8 million, respectively, related to net working capital finalization for the divestiture of our coordinated care and fire businesses. There was no (gain) loss on divestiture of businesses recorded for the three and six months ended June 30, 2026.
8. Realized and unrealized (gain) loss, net represents changes in the fair value of equity securities for the three and six months ended June 30, 2026 and 2025, respectively. Additionally, during the six months ended June 30, 2026, a certain cost method investment was sold for a (gain) of ($6.9) million. There was a loss on a strategic cost investment of $6.2 million for the six months ended June 30, 2025
9. We use the equity method of accounting to recognize our proportionate share of net income (loss) generated by our noncontrolling interest in Banner health system emergency air joint venture in Arizona.

Global Medical Response

Net Leverage Calculation

(unaudited in millions)	June 30, 2026	June 30, 2025
Senior Secured Term Loans	$2,912	$3,543
Senior Secured Notes	1,000	605
Other Long-Term Debt & Finance Leases	656	573
Redeemable Preferred Stock [1]	-	1,134
Total Debt	$4,568	$5,855
(-) Cash and Equivalents	420	462
Net Debt	**$4,148**	**$5,393**
06/2026 TTM Adjusted EBITDA	**$1,175**	**$1,260**
Leverage, x	**3.5x**	**4.3x**

(1) Includes stated value and accrued dividend from issuance in May 2024 to redemption/exchange on April 14, 2026.

Global Medical Response